Empowered Funds LLC Invests $1.80 Million in Inspire Medical Systems, Inc. $INSP

Empowered Funds LLC purchased a new stake in Inspire Medical Systems, Inc. (NYSE:INSP) during the 1st quarter, HoldingsChannel reports. The fund purchased 34,876 shares of the company’s stock, valued at approximately $1,799,000.

Other institutional investors also recently modified their holdings of the company. CWM LLC raised its holdings in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after acquiring an additional 242 shares during the period. Havemeyer Place LP bought a new position in shares of Inspire Medical Systems in the fourth quarter worth $39,000. V Square Quantitative Management LLC purchased a new position in shares of Inspire Medical Systems in the fourth quarter valued at $40,000. Smartleaf Asset Management LLC grew its position in shares of Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after purchasing an additional 205 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Inspire Medical Systems by 21,266.7% during the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after purchasing an additional 638 shares during the period. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on INSP. Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. UBS Group initiated coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 price target on the stock. Bank of America lowered shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective for the company. in a research report on Friday, May 22nd. Wells Fargo & Company reduced their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Finally, Stifel Nicolaus set a $75.00 price target on shares of Inspire Medical Systems in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $68.00.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $58.91 on Friday. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03. The company has a fifty day moving average of $47.26 and a 200-day moving average of $54.48. The company has a market capitalization of $1.70 billion, a P/E ratio of 12.75, a P/E/G ratio of 4.55 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The business had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The firm’s revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.